The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages

Lancet Infect Dis. 2022 Dec;22(12):1665-1666. doi: 10.1016/S1473-3099(22)00693-4. Epub 2022 Oct 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2
  • Vaccines*

Substances

  • cilgavimab
  • Antibodies, Viral
  • Vaccines
  • Antibodies, Neutralizing